Microbiome

Overview

The microbiome refers to the entire collection of microorganisms and their genes associated with a particular habitat. In humans the term usually refers to the gut microbiome, but skin, oral cavity, urogenital tract, and lungs all host distinct microbial ecosystems that interact with host physiology.

The gut microbiome alone contains an estimated 100 trillion cells spanning 500–1000 bacterial species, encoding more than 100 times the number of genes in the human genome. It behaves like an organ — metabolically active, hormonally responsive, and critical for homeostasis.

Detailed Explanation

Composition

Healthy adult gut communities are dominated by Firmicutes and Bacteroidetes, with smaller contributions from Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria. Composition is shaped by:

• Diet — especially fiber, polyphenols, and fermentable carbohydrates
• Antibiotic exposure
• Host genetics
• Age, geography, and lifestyle
• Delivery mode at birth and early feeding

Metabolic functions

The gut microbiome:

• Produces short-chain fatty acids (acetate, propionate, butyrate) from dietary fiber
• Synthesizes vitamins (K, B12, folate, biotin)
• Metabolizes bile acids
• Transforms drugs and xenobiotics, often altering bioavailability
• Produces neuroactive compounds (GABA, serotonin precursors, tryptophan derivatives)
• Competes with pathogens for niche space and nutrients

Immune education

The microbiome trains the immune system from birth, shaping tolerance, T regulatory cell populations, and barrier integrity. Dysbiosis is implicated in inflammatory bowel disease, asthma, eczema, type 1 diabetes, and autoimmune conditions.

Gut-brain axis

Microbiome-derived metabolites reach the brain via the vagus nerve, circulating cytokines, and bloodstream. Germ-free animals exhibit altered neurotransmitter profiles, behavior, and stress responses — evidence that gut microbes influence neurobiology.

Relevance to Peptide Therapeutics

Oral peptide bioavailability

Most peptides taken orally are rapidly degraded by gut proteases — many of them microbial — and by hydrolysis in the gastrointestinal lumen. The microbiome is a major reason peptide bioavailability is typically under 1% for oral formulations.

Drug metabolism

Gut microbes perform reductions, hydrolyses, deconjugations, and demethylations that can activate prodrugs, inactivate active drugs, or produce toxic metabolites. The composition of the microbiome can therefore shift peptide pharmacokinetics.

Peptide-microbiome crosstalk

Antimicrobial peptides (defensins, cathelicidins, LL-37) shape gut microbial communities. Some therapeutic peptides — including BPC-157 — have reported effects on intestinal healing and barrier function that may partially reflect microbiome changes.

Therapeutic microbiome targeting

• Fecal microbiota transplant for recurrent C. difficile
• Prebiotics and probiotics to reshape communities
• Postbiotics — defined microbial metabolites used as drugs
• Engineered live biotherapeutics — programmed bacteria delivering therapeutic peptides or sensing disease markers

Microbiome and Metabolic Disease

Obesity, type 2 diabetes, and NAFLD are all associated with microbiome shifts. Short-chain fatty acids influence GLP-1 and PYY secretion from gut L cells, linking fiber intake to appetite regulation. Peptide therapies for metabolic disease may indirectly modulate, or be modulated by, the microbiome.

Measurement

• 16S rRNA sequencing — profiles bacterial taxa
• Shotgun metagenomics — sequences all microbial DNA
• Metabolomics — measures microbial metabolites
• Metatranscriptomics — measures which microbial genes are expressed

Summary

The microbiome is a deeply integrated organ of microbial origin. It interacts with every major therapeutic class, including peptides, by shaping absorption, metabolism, immunity, and signaling. Understanding microbiome status is increasingly part of personalized peptide therapy.